CARDIFF ONCOLOGY INC's ticker is CRDF and the CUSIP is 14147L108. A total of 59 filers reported holding CARDIFF ONCOLOGY INC in Q3 2023. The put-call ratio across all filers is 0.28 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,846 | -5.4% | 7,803 | +0.1% | 0.00% | – |
| Q2 2023 | $11,465 | -10.8% | 7,799 | +0.2% | 0.00% | – |
| Q1 2023 | $12,849 | +445.4% | 7,787 | +362.7% | 0.00% | – |
| Q4 2022 | $2,356 | +17.8% | 1,683 | +0.9% | 0.00% | – |
| Q3 2022 | $2,000 | -50.0% | 1,668 | -1.3% | 0.00% | – |
| Q2 2022 | $4,000 | -82.6% | 1,690 | -81.8% | 0.00% | – |
| Q1 2022 | $23,000 | -81.9% | 9,310 | -56.0% | 0.00% | – |
| Q4 2021 | $127,000 | +535.0% | 21,149 | +609.7% | 0.00% | – |
| Q3 2021 | $20,000 | +233.3% | 2,980 | +225.7% | 0.00% | – |
| Q2 2021 | $6,000 | -89.3% | 915 | -84.7% | 0.00% | – |
| Q1 2021 | $56,000 | -92.6% | 5,968 | -85.8% | 0.00% | – |
| Q4 2020 | $757,000 | +9362.5% | 42,120 | +8047.0% | 0.00% | – |
| Q3 2020 | $8,000 | – | 517 | +649.3% | 0.00% | – |
| Q2 2020 | $0 | – | 69 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 2,522,083 | $16,797,000 | 13.61% |
| Octagon Capital Advisors LP | 982,753 | $6,545,000 | 1.61% |
| Altium Capital Management LP | 348,888 | $2,324,000 | 0.61% |
| ACT CAPITAL MANAGEMENT, LLC | 102,500 | $683,000 | 0.35% |
| Eventide Asset Management | 1,670,399 | $11,125,000 | 0.15% |
| Artal Group S.A. | 750,000 | $4,995,000 | 0.11% |
| Virtus ETF Advisers LLC | 25,770 | $172,000 | 0.08% |
| HighVista Strategies LLC | 15,501 | $103,000 | 0.07% |
| ELKHORN PARTNERS LIMITED PARTNERSHIP | 13,500 | $90,000 | 0.05% |
| SCHOLTZ & COMPANY, LLC | 16,625 | $111,000 | 0.04% |